Similarly, we recently showed that cancer cells that harbour a gain-of-function TP53 mutation have enhanced TNFα/NFκB paracrine signalling in pre-clinical models of PDAC82, which in turn educates adjacent CAFs, genetically tuning them to secrete aberrant levels of perlecan, which is pro-metastatic and chemoprotective at the liver82. The gene discussed is TNF; the disease is cancer.